−0.55 PLN
−28.12 M PLN
167.04 M PLN
23.83 M
About CLNPHARMA
Sector
CEO
Maciej Wieczorek
Headquarters
Lomianki
Website
Founded
2002
ISIN
PLCLNPH00015
FIGI
BBG00DSJ1T59
Celon Pharma SA is a pharmaceutical company, which engages in the research and manufacture of modern drugs. The firm's products include Aromek, Donepex, Ketrel, Salmex, and Valzek. It operates through the Generic Drug and Innovative segments. The Generic Drug segment pertains to the manufacture and sale of drugs registered and authorized for marketing. The Innovative segment involves activities that develop the documentation on the basis of which a drug could be registered or commercialized at the stage prior to drug registration. The company was founded by Maciej Wieczorek on June 20, 2002 and is headquartered in Lomianki, Poland.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CLN is 27.00 PLN — it has decreased by −2.17% in the past 24 hours. Watch CLNPHARMA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GPW exchange CLNPHARMA stocks are traded under the ticker CLN.
CLN stock has fallen by −1.28% compared to the previous week, the month change is a −4.59% fall, over the last year CLNPHARMA has showed a 78.81% increase.
We've gathered analysts' opinions on CLNPHARMA future price: according to them, CLN price has a max estimate of 39.00 PLN and a min estimate of 12.00 PLN. Watch CLN chart and read a more detailed CLNPHARMA stock forecast: see what analysts think of CLNPHARMA and suggest that you do with its stocks.
CLN stock is 4.15% volatile and has beta coefficient of 0.47. Track CLNPHARMA stock price on the chart and check out the list of the most volatile stocks — is CLNPHARMA there?
Today CLNPHARMA has the market capitalization of 1.45 B, it has decreased by −4.96% over the last week.
Yes, you can track CLNPHARMA financials in yearly and quarterly reports right on TradingView.
CLNPHARMA revenue for the last quarter amounts to 65.60 M PLN, despite the estimated figure of 63.20 M PLN. In the next quarter, revenue is expected to reach 60.15 M PLN.
CLN net income for the last quarter is −15.67 M PLN, while the quarter before that showed −14.97 M PLN of net income which accounts for −4.69% change. Track more CLNPHARMA financial stats to get the full picture.
Yes, CLN dividends are paid annually. The last dividend per share was 0.08 PLN. As of today, Dividend Yield (TTM)% is 0.30%. Tracking CLNPHARMA dividends might help you take more informed decisions.
As of Nov 11, 2024, the company has 515.00 employees. See our rating of the largest employees — is CLNPHARMA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CLNPHARMA EBITDA is −24.71 M PLN, and current EBITDA margin is −16.05%. See more stats in CLNPHARMA financial statements.
Like other stocks, CLN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CLNPHARMA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CLNPHARMA technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CLNPHARMA stock shows the buy signal. See more of CLNPHARMA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.